LP-410 is under clinical development by Lipella Pharmaceuticals and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-410’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LP-410 is under development for the treatment of graft versus host disease. It is administered through oral route.
Lipella Pharmaceuticals overview
Lipella Pharmaceuticals (Lipella Pharma) operates as a clinical-stage biotechnology company that discovers, develops, and commercializes lipid-based therapies. The company provides product LP-10, LP-310. It offers LP-10 product which is a proprietary liposomal formulation of tacrolimus, a potent immunosuppressant that also exhibits anti inflammatory effects. Lipella Pharma offers products for common bladder syndromes such as interstitial cystitis, refractory overactive bladder and hemmorhagic cystitis. The company also provides transmucosal therapy for smooth muscle dysfunction. It also develops new drugs to treat patients with urinary bladder diseases and disorders. The company also conducts clinical trials in different areas. Lipella Pharma is headquartered in Pittsburgh, Pennsylvania, the US.
For a complete picture of LP-410’s drug-specific PTSR and LoA scores, buy the report here.